Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
RenJi Hospital
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06567080CT.gov JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Systemic Lupus Erythematosus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jwcar201 (this asset) | RenJi Hospital | P1 | CC · 43 |
| Dehydroepiandrosterone | National Center for Research Resources (NCRR) | P3 | BB |
| Warfarin | University College, London | P2 | B |
| Rivaroxaban | University College, London | P2 | B |
| Cytarabine | National Center for Research Resources (NCRR) | P2 | B |
| Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)- | Mayo Clinic | P2 | B |
| Monovalent [B.1.351] Cov2 Pres Dtm-As03 | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Moderna Covid-19 Vaccine Rna | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Bcma-Cd19 Ccar T Cells | Peking University People's Hospital | P2 | CCC |
+26 more in the Systemic Lupus Erythematosus cohort
Other indications for Jwcar201
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Neoplasm | — | P1 | CC · 43 |
| Autoimmune Disease | — | P1 | CC · 41 |
| Diffuse Large B-Cell Lymphoma | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DehydroepiandrosteroneNational Center for Research Resources (NCRR)BB
- WarfarinUniversity College, LondonB
- RivaroxabanUniversity College, LondonB
- CytarabineNational Center for Research Resources (NCRR)B
- Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)-Mayo ClinicB
Citation
Floatz Terminal. Jwcar201 in Systemic Lupus Erythematosus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jwcar201-systemic-lupus-erythematosus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →